At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 51 enrolled
Drug / intervention
Treprostinil Inhalation Powderdrug
Likely dose
Treprostinil Inhalation Powder 48 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
In Brief
A Phase 1 clinical trial evaluating Treprostinil Inhalation Powder for Pulmonary Arterial Hypertension. Completed, enrolled 51 participants across 16 sites.
Detailed Summary
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartSep 2019
Primary CompletionAug 2023
TodayJul 2026
First PostedMay 15, 2019
Enrollment StartSep 17, 2019
Primary CompletionAug 22, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.1 years ago
Interventions
Treprostinil Inhalation Powderdrug
Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)